About
Small Molecules, Gene Therapy, Antisense Oligonucleotides, Biologics
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalGene Therapy, RNA & Peptide TherapyBiotech
Team (29)
Amy Bachrodt
Maze Therapeutics
team_member
Andrew Good
Maze Therapeutics
team_member
Atul Dandekar
Maze Therapeutics
team_member
Catherine Angell Sohn, Pharm.D.
FORMER Senior Vice President GLAXOSMITHKLINE; ADJUNCT PROFESSOR AT UCSF
Maze Therapeutics
executive
Charles Homcy
(observer)M.D., CEO; Partner, Third Rock Ventures
Maze Therapeutics
executive
Charles Homcy, M.D.
FORMER CHAIRMAN OF THE MAZE BOARD, CHAIRMAN OF PHARMACEUTICALS AND LEAD DIRECTOR, BRIDGEBIO PHARMA
Maze Therapeutics
board_chairlead_independent_director
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
177
By Phase
PHASE2: 1PHASE1: 1
By Status
RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06830629Lead Sponsor
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
PHASE2Recruiting
56 participants
Started: Feb 5, 2025 · Completed: Sep 30, 2026
NCT05249621Lead Sponsor
A Randomized Phase 1 of of MZE001 in Healthy Volunteers
PHASE1Completed
121 participants
Started: Feb 7, 2022 · Completed: Dec 21, 2022
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...